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Adequate sleep is essential for physical and mental health. We
previously identified a missense mutation in the human DEC2 gene
(BHLHE41) leading to the familial natural short sleep behavioral trait.
DEC2 is a transcription factor regulating the circadian clock in mam-
mals, although its role in sleep regulation has been unclear. Here we
report that prepro-orexin, also known as hypocretin (Hcrt), gene
expression is increased in the mouse model expressing the mutant
hDEC2 transgene (hDEC2-P384R). Prepro-orexin encodes a precursor
protein of a neuropeptide producing orexin A and B (hcrt1 and
hcrt2), which is enriched in the hypothalamus and regulates main-
tenance of arousal. In cell culture, DEC2 suppressed prepro-orexin
promoter-luc (ore-luc) expression through cis-acting E-box elements.
The mutant DEC2 has less repressor activity than WT-DEC2, resulting
in increased orexin expression. DEC2-binding affinity for the prepro-
orexin gene promoter is decreased by the P384Rmutation, likely due
to weakened interactionwith other transcription factors. In vivo, the
decreased immobility time of the mutant transgenic mice is attenu-
ated by an orexin receptor antagonist. Our results suggested that
DEC2 regulates sleep/wake duration, at least in part, by modulating
the neuropeptide hormone orexin.
sleep | behavior | genetics | mouse model
The timing and duration of sleep are determined by complexmechanisms. Although the circadian clock has been shown to
be an integral component of timing regulation (1), the mecha-
nism of duration modulation is not clear. Using genetics of hu-
mans with altered sleep patterns, we have reported a number of
mutations in circadian clock genes that affect the timing or dura-
tion of sleep (2–7). Among these, we reported the Pro384Arg
(P384R) mutation (originally called P385R; ref. 5) in the DEC2
gene (BHLHE41) that leads to the natural short sleep phenotype
in one human family. DEC2 is a basic helix-loop-helix transcrip-
tion factor suppressing E-box–mediated transcription (8), which is
the basis of the negative feedback loop in the circadian clock (9).
We have shown that mouse and Drosophila models carrying the
hDEC2-P384R transgene demonstrate shortened total sleep time
compared with wild-type (WT) animals (5). A recent study also
reported that carriers of a Tyr362His (Y362H) variant in the hu-
man DEC2 gene are short sleepers who are resistant to sleep
deprivation (10), further supporting the important role of DEC2 in
sleep homeostasis. However, an understanding of the altered
molecular function of mutant DEC2 and of the normal role of
wild-type (WT) DEC2 in regulating sleep duration has remained
elusive. Although DEC2 is considered a clock protein, knockout of
Dec2 and double knockout of Dec1 and 2 result in only a subtle
circadian rhythm phenotype (11). Furthermore, DEC2 mutations
affect sleep rebound after sleep deprivation in mouse models and
humans (5, 10), and Dec1/2 double knockout influences sleep ar-
chitecture (12). Thus, it is likely that DEC2 regulates sleep ho-
meostasis directly rather than through clock regulation.
In the present study, we found that prepro-orexin [also known
as hypocretin (Hcrt)] expression is enhanced in the mouse model
carrying the human DEC2-P384R gene. Prepro-orexin encodes a
neuropeptide precursor protein producing orexin A and orexin
B (hcrt1 and 2), which are enriched in the hypothalamus and are
involved in many physiological processes, including arousal
(especially consolidation of wakefulness), appetite, mood, re-
ward, and autonomic function (13). Our results indicate that
DEC2 binds to the prepro-orexin promoter to suppress its ex-
pression, and that the repressor function of DEC2 is altered by
the P384R mutation. We conclude that DEC2 regulates the
orexin signaling pathway, thus affecting human sleep behavior.
Results
To explore the mechanism underlying the behavioral phenotype
of decreased sleep time in DEC2 mutation carriers, we examined
the expression of genes regulating sleep homeostasis in a mouse
model of the human DEC2 mutation. We found that prepro-orexin
(Hcrt) gene expression was up-regulated in the hypothalamus of
hDEC2-P384R transgenic (Tg) mice compared with hDEC2-WT
Tg mice (Fig. 1A). Mammals have two receptors for orexin pep-
tides, orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R)
(13). In hDEC2 mutant mice, the expression of OX2R was also
slightly increased (Fig. 1A). To confirm the up-regulation of orexin
at the protein level, we analyzed its expression in the lateral hy-
pothalamus at zeitgeber time 1 (ZT1) by immunohistochemistry
using an antibody recognizing orexin precursor protein and the
orexin A peptide. The number of orexin-positive cells was in-
creased by the P384R mutation (Fig. 1B). We also generated
FLAG-tagged hDEC2 BAC Tg mice harboring the Y362H mu-
tation and found that these mice showed increased prepro-orexin
levels (Fig. S1A). Tg mice expressing either Y362H-DEC2 or
P384R-DEC2 exhibited increased activity and decreased rest
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behavior (Fig. S1B), similar to what has been shown previously in
the P384R mutant mice (5).
Deletion of orexin neurons or knockout of prepro-orexin or
orexin receptor genes results in narcolepsy in mammals, indicating
that orexin signaling plays a critical role in maintaining arousal
and consolidation of sleep (13). Furthermore, administration of
orexin A or selective activation of the orexin neurons increases
arousal and decreased sleep duration (13). Therefore, modulating
orexin expression is a key step in sleep/wake regulation. Since the
expression levels of prepro-orexin were increased in the mutant
mice, we explored the possibility that DEC2 directly modulates
the expression of orexin. Previous studies indicated that the 3.2-kb
promoter region of prepro-orexin is sufficient for endogenous ex-
pression, which was confirmed by generating prepro-orexin
promoter-driven LacZ Tg mice (14). Within this 3.2-kb region,
two elements—orexin regulatory elements 1 and 2 (OE1 and
OE2)—were recognized because of a high similarity between mice
and humans. Of these, OE1 plays a more important role in reg-
ulating orexin expression (Fig. 2A) (15). To examine the role of
DEC2 in orexin expression, we cloned promoter regions of the
prepro-orexin gene including only OE1 or both OE1 and OE2. A
luciferase assay using prepro-orexin promoter luciferase (ore-luc)
constructs showed that DEC2 protein decreased ore-luc activity,
especially with the 0.6-kb region of the promoter containing OE1
(Fig. 2B). We then examined the occupancy of endogenous mouse
DEC2 in the promoter region of the prepro-orexin gene in brain
and observed a chromatin immunoprecipitation (ChIP) signal in
the OE1 region (0.6 kb; primer sets 1 and 2) but not outside of the
3.2-kb region (primer set 3) (Fig. 2C).
DEC1 and DEC2 directly or indirectly (through interaction
with other transcription factors) bind to DNA and modulate the
transactivation of CLOCK, BMAL1, MYC, MyoD1, and E12/47,
all of which are E-box–binding transcription factors (8, 9, 16–18).
DEC1/2 proteins form homodimers and directly bind to class B
E-boxes (CACGTG), which is the CLOCK-BMAL1 consensus
sequence (8, 19). DEC1/2 also form complexes with other tran-
scription factors, such as MyoD1 and its binding partner E12/47,
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Fig. 1. Expression of orexinergic genes is up-regulated in the hDEC2-P384R
mice. (A) mRNA levels of prepro-orexin, orexin receptor1 (OX1R), and orexin
receptor2 (OX2R) in hypothalamus of hDEC2 BAC Tg mice at ZT1. mRNA
levels were analyzed by real-time PCR using specific primers of indicated
genes and normalized to Gapdh. Data are shown as mean ± SEM. n = 3. *P <
0.05, Student’s t test. (B) Immunohistochemistry of orexin A in the lateral
hypothalamus of the BAC Tg mice at ZT1. Prepro-orexin and orexin A were
immunostained with anti-orexin A antibody, and orexin A-positive cells were
counted. Three representative images with the same experimental condition
were shown. Data were collected from ∼30 slices and averaged for each
mouse. Data are shown as mean ± SEM. n = 5. *P < 0.05, Student’s t test.
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Fig. 2. DEC2 inhibits E-box–mediated transcription of prepro-orexin.
(A) Schematized model of the human prepro-orexin gene promoter. OE1–
3 are the primer sets used for ChIP assays in C. (B) Luciferase assay in
HEK293 cells. DEC2 expression inhibits ore-luc activity. Firefly luciferase ac-
tivity was normalized to Renilla luciferase activity. (C) ChIP with mouse brain
and anti-DEC2 antibody. Brains (including hypothalami) were collected at
ZT8 and homogenized. ChIP signals were determined by real-time PCR using
the primer sets shown in A. Signals were normalized to normal mouse IgG.
Data are shown as mean ± SEM. n = 4. *P < 0.05, Tukey’s test. (D) Luciferase
assay using E-box mutant constructs. Mutations are shown at the bottom of
A. DEC2 repressor activity was not observed for E-box mutant ore-luc. Data
are shown as mean ± SEM (n = 3). *P < 0.05, two-way ANOVA followed by
post hoc test. (E) The effect of transcription factors known to bind E-boxes.
FLAG-tagged transcription factors (TF) were expressed in HEK293 cells. C/B
indicates FLAG-tagged CLOCK and BMAL1. Data are shown as mean ± SEM.
n = 4. *P < 0.05, Tukey’s test. (F) The effect ofMYOD1 andMYF5 knockdown
by shRNA on ore-luc activity. shRNA of MYOD1/MYF5 (with/without TCF3
shRNAs) were transfected into HEK293 cells. Data are shown as mean ± SEM.
n = 4. *P < 0.05, Tukey’s test.
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to bind to another type of E-box sequence (CAGCTG) (18, 20)
found in promoter region of orexin (Fig. 2A). Thus, we in-
troduced mutations in putative E-boxes in the 0.6-kb region to
examine the effect on DEC2 repressor activity (Fig. 2A). The
mutations at E-boxes 1 and 2 attenuated DEC2 activity, sug-
gesting that DEC2 represses ore-luc activity via these two ele-
ments (Fig. 2D). We then examined which binding partner of
DEC2 is involved in orexin regulation mediated by these E-box
sequences. Among E-box–binding transcription factors, MyoD1
dramatically activated ore-luc (Fig. 2E). In contrast, the trans-
activation of ore-luc by MYC and CLOCK/BMAL1 was much
less than that by MyoD1.
Although MyoD1 is known for its role in regulating muscle cell
differentiation and muscle regeneration, it is nonetheless widely
expressed in many tissues, including brain. In the regulation of
muscle differentiation, MyoD1 cooperates with E12 and E47
proteins, which are splice variants encoded by the TCF3 gene
(16, 17, 20, 21). MyoD1/E47 heterodimer activates creatine ki-
nase, M-type (Ckm) gene expression (a physiological target of
MyoD1) (20), and DEC2 serves as repressor for MyoD1/
E47 activity on Ckm expression. Thus, we asked whether E12/
E47 also influences MyoD1 activity on ore-luc. In contrast to the
case for Ckm, we found that overexpression of E12 and E47
inhibited MyoD1 activation of ore-luc. We then knocked down
MYOD1 and its homolog (MYF5), which has a redundant role in
muscle differentiation (22). Double knockdown of MYOD1 and
MYF5 by shRNAs resulted in decreased ore-luc activity, while
additional knockdown of TCF3 eliminated the reduction almost
completely (Fig. 2F), consistent with E12 and E47 serving as
repressors of MyoD1 for the prepro-orexin promoter. Taken to-
gether, these results suggest that MyoD1, E12, and E47 partici-
pate in the regulation of prepro-orexin expression, with E12 and
E47 acting as repressors of MyoD1.
Interestingly, although DEC2 strongly inhibited ore-luc acti-
vation by MyoD1 (Fig. 3A), DEC2 repressor activity was com-
pletely abolished by the expression of E12 or E47 (Fig. 3A), with
no effect on DEC2 expression levels (Fig. S2). It is possible that
in the formation of functional complexes of transcription factors
(MyoD1, E12/47, and DEC2), excessive E12/47 can interfere with
proper DEC2 interaction and abolish DEC2 function. To confirm
that E-box1 is the target of MyoD1, we used the mutated E-box
sequences described above (Fig. 2 A and D). The mutations in
E-box1 reduced MyoD1 transactivation and attenuated the
DEC2 repressor activity of MyoD1 (Fig. 3B). Consistent with this,
E-box1 is identical to the consensus sequence for MyoD1 rather
than other DEC2-binding proteins, such as CLOCK and BMAL1.
Moreover, sequence analysis revealed that only E-box1 is con-
served in humans and mice prepro-orexin promoters, implying that
E-box1 is more likely to be functional in vivo. However, mutations
spanning all E-boxes within the 0.6-kb region (E-box1, E-box2,
and E-box3) did not completely abolish MyoD1 transactivation
(Fig. S3), suggesting that additional cis elements for MyoD1 exist
in this region. We then examined the effect of the P384R mu-
tation on DEC2 activity for ore-luc. We and another group have
previously shown that the P384R mutation decreased the DEC2
repressor activity of CLOCK-BMAL1–mediated Per1-luc and
Per2-luc transactivation (5, 10). Similarly, the P384R mutation
reduced DEC2 repression of MyoD1 activity on promoter ele-
ments in both 0.6- and 3.2-kb ore-luc constructs (Fig. 3C). These
data indicate that DEC2 and its binding partner MyoD1 inhibit
and activate orexin expression, respectively. More importantly,
the human mutation of DEC2 resulted in reduced DEC2 re-
pressive activity and thus increased ore-luc activity. We also
confirmed these findings in another cell line, SH-SY5Y, a
neuroblastoma-derived cell line (Fig. 3D), because responses of
the orexin promoter can vary among different cell lines (23).
Taken together, our in vitro data are congruent with the finding
that orexin expression is up-regulated in the mouse model of the
human mutations (Fig. 1A).
We next asked how the mutation reduces DEC2 activity. We
found that the protein levels of DEC2-WT, DEC2-P384R, and
DEC2-Y362H were comparable, as has been reported previously
(10). The degradation rate of DEC2 was not affected by either
mutation (Fig. S4). A previous study demonstrated that the in-
teraction with MyoD1 in vitro is reduced by deletion of the Gly-
Ala rich domain of DEC2 (8, 20), in which the two mutations
reside. Thus, the mutations may affect the interaction of DEC2
with other transcription factors. A coimmunoprecipitation experi-
ment showed that the interaction of DEC2 with E12 was greatly
strengthened by the expression of MyoD1 (Fig. 4A), implying that
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Fig. 3. The P384R mutation decreases DEC2 repressor activity. (A) Over-
expression of E12 (Top) and E47 (Bottom) abrogated the effect of DEC2.
HEK293 cells were transfected with the indicated plasmids. Data are shown as
mean ± SEM. n = 4. *P < 0.05, Tukey’s test. (B) The mutation in E-box1 reduced
MyoD1 activity and DEC2 repressive activity in both 0.6- and 3.2-kb ore-luc
constructs. Data are shown as mean ± SEM. n = 4. *P < 0.05, Tukey’s test.
(C) The effect of the P384R mutation on DEC2 activity in HEK293 cells. Data are
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3436 | www.pnas.org/cgi/doi/10.1073/pnas.1801693115 Hirano et al.
DEC2, MyoD1, and E12 form a complex, and that DEC2 binds to
a MyoD1/E12 complex. We found that the complex formation of
DEC2, MyoD1, and E12 was weakened by the P384R mutation,
but not by the Y362H mutation, in cell culture (Fig. 4 A and B).
It is possible that the reduced interaction of DEC2-P384R with
E12/47 could impact the occupancy of DEC2 on the prepro-
orexin promoter. To compare the DNA-binding affinity of WT
and mutant DEC2 in brain, we used H11 locus-specific DEC2 Tg
mice, in which a conditional allele of the gene was integrated into
theH11 locus, so that we can exclude an effect of copy number and
expression level of transgenes (Fig. S5A). After crossing these mice
with Nestin-Cre Tg mice, the expression of Myc-tagged DEC2
proteins was driven by a constitutive promoter—the cytomegalovirus
(CMV) early enhanced/chicken beta actin (CAG) promoter—and
comparable amounts of DEC2 proteins were detected in mouse
brain (Fig. S5B). We confirmed that in the H11 mice, DEC2-Myc
binds to the E-box–containing promoters of prepro-orexin and Dbp
genes, as expected (Fig. S5C); however, weakened binding of
mutant DEC2 to the prepro-orexin promoter was observed in
H11 P384R-DEC2 Tg mice (Fig. 4C). In contrast, there was no
obvious effect of the Y362H mutation on the interaction of
DEC2 with E12 in cell culture (Fig. 4 A and B), suggesting that a
different molecular mechanism is responsible for the reduced
repressor activity of DEC2-Y362H.
To further investigate the dynamics of the interaction of E12/
47 with DEC2, we examined the effect of TCF3 knockdown on
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Fig. 4. The P384R mutation decreases DEC2 binding to E12 and DNA. (A) Co-IP of E12 and DEC2 expressed in HEK293 cells. DEC2-Myc-His was immuno-
precipitated with anti-Myc antibody. Results were obtained from three independent experiments. (B) The effect of the mutation on the interaction of
DEC2 with E12 in HEK293 cells. (C) ChIP assay of DEC2 in mouse brain from H11 Tg mice. DEC2-Myc proteins were precipitated with anti-DEC2 antibody, and
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competes with transcription factors (MyoD1, E12, and E47) and suppresses the transcriptional activity of orexin. Overexpressed E12 or E47 likely interfere with
the binding of DEC2 to MyoD1/DNA. The P384R mutation in DEC2 decreased the interaction with E12 and DNA-binding affinity, leading to up-regulation
of orexin.
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DEC2 repressor activity. TCF3 knockdown by siRNA decreased
DEC2 repressive activity in a small, but statistically significant
way (Fig. 4D). These results suggested that E12/47 helps to re-
cruit DEC2 to the complex and to E-boxes. To test whether
orexin mediates the sleep phenotype altered in the DEC2mutant
mice, we orally administrated orexin receptor antagonist to the
Tg mice and recorded their wake/rest behavior. As shown pre-
viously (Fig. S1B), hDEC2-P384R mice have decreased total rest
time compared with hDEC2-WT Tg mice, especially during the
first half of the dark phase (Fig. 4E). Interestingly, the admin-
istration of MK-6096, a nonselective orexin receptor antagonist,
partially cancelled the phenotype of decreased sleep time ob-
served in hDEC2-P384R mice (Fig. 4E).
Taken together, the results presented here indicate that
MyoD1 activates prepro-orexin gene expression, and that DEC2 is
a repressor of this activation (Fig. 4F). Prepro-orexin expression
and orexin levels show daily rhythms in hypothalamus and cere-
brospinal fluid (24, 25). DEC2 expression oscillates in a circadian
manner (9, 26) and thus may contribute to the expression rhythms
of prepro-orexin. Our results suggest that E12/47, MyoD1, and
DEC2 form a complex to regulate prepro-orexin expression. This
complex formation is reduced by the P384R mutation, leading to
orexin up-regulation. Overexpression of E12 or E47 attenuates
DEC2 repressor activity, possibly because the interaction of
DEC2 and E12 depends on MyoD1 (Fig. 4A), and excessive ac-
cumulation of E12/47 may prevent the DEC2–MyoD1 interaction
(Fig. 4F, Bottom).
Discussion
Here we have demonstrated that DEC2 protein physically binds
to the orexin promoter in mouse brain and regulates expression
of the gene through E-box cis elements. The 3.2-kb 5′ UTR of
the prepro-orexin promoter containing the E-box is sufficient for
the endogenous expression of orexin (14), and activation of the
cells driven by this promoter region using optogenetic manipu-
lation was sufficient to induce wakefulness (13, 27). Therefore,
our findings provide insight into how orexin expression, which is
involved in many biological functions, is regulated at a molecular
level. We previously reported that the human DEC2 mutation
contributes to short sleep in humans and decreased sleep time in
other animals (flies and mice) (5), but the detailed mechanism
of these sleep phenotypes has remained elusive. In the present
study, we found that the mutation leads to increased orexin
expression in mice, contributing to our understanding of how
the mutation alters sleep architecture. Interestingly, we also
observed an increased level of orexin receptor 2 in the mutant
mice. A previous study showed that pharmacologic activation
of REV-ERB activity resulted in decreased prepro-orexin and
orexin receptor expression, while knockout of Reverbβ increased
expression (28). Thus, prepro-orexin and orexin receptor genes
likely are regulated by a similar mechanism. Administration of
orexin A peptide directly into the brain increased wakefulness
(13, 29), indicating the wake-promoting effect of orexin. Over-
expression of Hcrt caused consolidation of the active state and
reduced rest in zebrafish (30). This Tg zebrafish also showed
an insomnia-like phenotype, manifested as a decreased arousal
threshold (30). Furthermore, CAG promoter-driven prepro-
orexin in mice causes fragmentation of sleep without affecting
total sleep duration (31). The behavioral output of chronically
increased orexin expression might be more complex and makes
comparisons of acute and chronic models difficult to interpret.
It is possible that increased orexin expression within a physio-
logical range (not overexpression) at a specific time point (e.g.,
ZT1) may decrease the total duration of sleep. Importantly, the
sleep phenotype (in Tg mice) is attenuated by an orexin re-
ceptor antagonist, further confirming the connection between
DEC2 and the orexin pathway (Fig. 4E).
As described above, despite the growing list of studies char-
acterizing physiological changes resulting from modulation of
orexin signaling, our understanding of the regulation of orexin
expression at a molecular level remains very limited. Previous
studies have shown that two transcription factors—Foxa2 and
NR6A1—enhance orexin expression, whereas the physiological
significance of these proteins in sleep regulation has not yet been
determined (32, 33). IGFBP3 has been shown to decrease orexin
expression in cell culture, and hIGFBP3 Tg mice have exhibited
decreased orexin levels and wake times (23), consistent with our
results (i.e., increased orexin and increased daily active time).
Here we have identified additional proteins (DEC2, MyoD1, and
E12/47) as regulators of orexin promoter activity. MyoD1 elevates
ore-luc activity, while the binding partners E12 and E47 inhibit
MyoD1-mediated transactivation (Fig. 2E).
Our results suggest that MyoD1, E12, and DEC2 form a com-
plex, because the interaction of DEC2 with E12 was significantly
strengthened by MyoD1 expression (Fig. 4A). Our in vitro studies
show that the reduction in DEC2 repressor activity due to the
P384R mutation resulted from altered binding to E12 and DNA.
Thus, it is likely that MyoD1/E12 functions in the recruitment of
DEC2 (Fig. 4 D and F, Top). However, we also observed that
overexpression of E12 or E47 cancelled the effect of DEC2 (Fig.
3A). We hypothesize that overexpressing E12/47 can compete with
MyoD1 binding to E-boxes, inhibiting the ability of DEC2 to bind
to E-boxes, because DEC2 requires MyoD1/E12 heterodimer for
recruitment (Fig. 4F, Bottom, Right). Another possibility is that
overexpressed E12/47 cannot be replaced by DEC2 in binding to
E-boxes (Fig. 4F, Bottom, Left), suggesting complex dynamics of
transcription factors. Orchestration of these transcription regula-
tors is expected to contribute to the time-dependent regulation of
the sleep hormone, orexin, while temporal dynamics of these
regulators on the E-box will require further study.
Collectively, our results suggest that the role of DEC2 in sleep
regulation is via orexin, at least in part. Consistent with the ca-
pacity of orexin to modulate sleep duration is recent evidence that
orexin antagonists, now available for the clinical treatment of in-
somnia, reliably increase total sleep time in both insomnia patients
(34–36) and healthy controls (37). Our findings demonstrate that
DEC2 is a target for modulating orexinergic signaling.
Materials and Methods
Mice. All experimental protocols were conducted according to the National
Institutes of Health guidelines for animal research and were approved by the
Institutional Animal Care and Use Committee at the University of California,
San Francisco. Male mice were entrained to a 12-h light:12-h dark cycle (LD
12:12) for at least 10 d with free access to food and water. For expression
rhythms of prepro-orexin and orexin receptors, mice were killed at ZT1, and
hypothalami were collected for mRNA extraction. For protein expression of
hDEC2-Myc in H11 Tg mice, mouse brains were collected at ZT1 and frac-
tionated into cytosolic and nuclear fractions as described previously (7).
Generation of BAC Tg Mice.We engineered a human BAC clone, CTD-2116MB,
containing the entire DEC2 gene in a 125-kb genomic insert to generate BAC
Tg mice. The BAC clone was modified by homologous recombination to
introduce the P384R or Y362H mutation and to add a FLAG tag sequence to
the C terminus of DEC2. All relevant segments generated by PCR and re-
combination were sequence-confirmed. BAC DNA was injected into C57B/6J
embryos following standard procedures. Tg lines were maintained by
backcrossing to C57B/6J mice.
Generation of H11 Tg Mice. For generation of H11 knockin Tg mice (38), we
used pBT346.2 plasmid provided by Devine Patrick and Benoit Bruneau,
University of California, San Francisco. A phosphoglycerate kinase (PGK)
promoter-neomycin (Neo) cassette sandwiched by loxP sequences was in-
serted behind the CAG promoter in the pBT346.2 vector. A cDNA encoding
Myc-tagged hDEC2 was inserted after the PGK-Neo cassette. Plasmid was
twice-purified by phenol-chloroform and then injected into embryos of
TARGATT knockin mice (38) in the FVB background together with φC31
integrase mRNA. Mice were crossed with β-actin-Flp Tg mice to remove the
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plasmid backbone before crossing to Cre Tg lines. For experiments, mice
were crossed with Nestin-Cre mice [Tg (Nes-cre)1Kln; The Jackson Labora-
tory] to activate expression of DEC2.
Luciferase Assay. HEK293 cells and SH-SY5Y cells were transfected with
prepro-orexin-luc (ore-luc) expression vector (pGL4.18; Promega), Renilla-luc
(pGL4.75; Promega) control vector, and indicated vectors. The luciferase
assay was performed using the Promega Dual-Luciferase Reporter Assay
System according to the manufacturer’s protocol. Bioluminescence was de-
tected with a Synergy H4 Hybrid Multi-Mode Microplate Reader (BioTek).
The bioluminescence of firefly Luc was normalized to that of Renilla Luc.
Immunoprecipitation. HEK293 cells were transfected with plasmid vectors
containing hDEC2-His-Myc, FLAG-MyoD1, or FLAG-hE12. At 48 h after trans-
fection, the cells were lysed in IP buffer (20 mM Hepes pH 7.8 at 4 °C, 137 mM
NaCl, 2 mM EDTA, 10% glycerol, and 0.1% Triton-X100), and the cell lysate
was incubated with anti-Myc antibody (Santa Cruz Biotechnology) overnight.
Protein G Sepharose (GE Healthcare) was added to the lysate, incubated for
2 h, and then washed three times, followed by Western blot analysis.
ANY-Maze Analysis of Tg Mice. All mice tested were ∼12-wk-old males
maintained on a C57BL/6J background. Mice were kept in individual cages
with free access to food and water. Mice were monitored by an infrared
camera and tracked by an automatic video tracking system (Stoelting). For Fig.
4E, mice were entrained to LD 12:12. PBS (control) or MK-6096 (25 mg/kg) was
injected with a 20 G animal feeding needle to mice at ZT11, and locomotor
activity was recorded from ZT12. For Fig. S1B, mice were entrained to LD 12:12,
and locomotor activity was recorded for 4 d. Walking distance and immobility
times were calculated using ANY-maze software.
Statistical Analysis. All error bars in the figures represent SEM. No statistical
analysis was used to predetermine the sample sizes. Experiments were not
randomized and were not analyzed blindly. Data were statistically analyzed
using R software. To assess statistical significance, data were obtained from
at least three independent experiments. For the comparison of two groups
with homogeneity of variance (evaluated by the F test), the two-tailed
paired Student’s t test was used. One-way or two-way ANOVA followed by
Tukey’s test was used for multiple comparisons with an assumption of
normal distribution. A P value <0.05 was considered to represent a statis-
tically significant difference.
More details on the methodology of this study are provided in SI Materials
and Methods.
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